Tirzepatide Stock Symbol: What It Is and What It Means (October 2026)

01 · The short answer

Which company and ticker is behind tirzepatide?

Eli Lilly and Company makes tirzepatide, and its shares trade under the symbol LLY on the New York Stock Exchange. A medicine is not listed on an exchange. Only the company that owns and sells it is, so there is no separate tirzepatide stock to buy.

You may see other listings that mention Lilly, such as depositary-style listings on foreign exchanges. These still represent the same company, not a separate tirzepatide product. Check a regulated broker or the exchange for the exact instrument you are looking at.

02 · What the ticker does not tell you

What the ticker does and does not tell you

The LLY ticker tells you which company is quoted. It does not tell you whether tirzepatide is available to you, what it costs in the UK, or whether it is suitable for you. Owning shares gives you no route to the medicine, and buying the medicine gives you no stake in the company.

Lilly's business is also wider than one drug. Share-price moves reflect the whole company, including expectations, competition and wider markets. We do not track share prices, so we cannot tell you why the stock has risen or fallen, or whether it is a good buy. For live quotes, use your broker, the exchange or a regulated financial data provider.

If you are curious about the legal side of the manufacturer's position, our guide on whether tirzepatide is patented explains it.

03 · If you want the medicine, not the shares

If you want the medicine, not the shares

UK adults can get Mounjaro on prescription after an online consultation. The Mounjaro pen starts at £169.99 for the 2.5mg starter, and a new customer's first 2.5mg pen is £129.99 with code FIRST40. Every later order is £25 off the standard price (code DOSE25). All six doses are in stock, and you can see the wider picture on our Mounjaro stock guide.

Planning the full cost? If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. A first year costs £2,711.88 if you settle at 5mg, up to £3,599.88 at 15mg. A new customer's first order is £40 less, and every later order £25 less.

Ordering works in three steps:

• Complete the free online consultation, a short health questionnaire with no obligation.
• A GPhC-registered prescriber reviews it. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Our registered pharmacy dispenses it, with same-day dispatch when ordered by 3pm and free next-day tracked delivery in temperature-controlled packaging.

04 · What tirzepatide is

What tirzepatide is and who makes it

Tirzepatide is the generic name of the active ingredient in Mounjaro, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Brand and generic names often cause confusion. The brand is what appears on the pen box. The generic name is the ingredient. If you have seen the term used on its own, our explainer on unbranded tirzepatide covers what that does and does not mean for UK patients.

05 · How it works

How tirzepatide works

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

This dual action distinguishes it from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic). Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹

Other compounds are being studied alongside it. Our page on bimagrumab and tirzepatide covers combination research, and the page on tirzepatide with pyridoxine explains what that pairing is.

06 · Who can use it

Who can be prescribed Mounjaro in the UK

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used alongside a reduced-calorie diet and increased physical activity. A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹

Mounjaro is also available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition. The NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions. Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁴⁶

07 · What trials show

What the main trial showed

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² For someone starting at 100 kg, 20.9% is about 21 kg.

These are trial averages, and individual results vary. Treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

Early changes can look different from trial endpoints. Our guide to Mounjaro before and after one month sets realistic expectations for the first weeks.

08 · Investor questions

Questions about Lilly shares we cannot answer

A forecast for 2026 or 2030 is a guess, whoever makes it. Share prices can fall as well as rise. No one can tell you whether it is too late to buy, and we would not trust a page that claimed to. For ownership, the company's regulatory filings list major shareholders. For performance, use live market data and independent, regulated financial advice.

Whether tirzepatide is right for you is a clinical decision made by a prescriber, based on your health.

09 · Buying safely

Buying tirzepatide safely in the UK

Tirzepatide is a prescription-only medicine, so any seller offering to supply without a consultation or prescription is a warning sign. Check that a pharmacy appears on the GPhC register. Ours is registration 9012878.¹² The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting side effects.⁷

We supply Mounjaro through official LillyDirect supply, direct from Eli Lilly's UK distribution, as genuine KwikPens. Aftercare includes ongoing monthly reviews, dose titration and side-effect support. Repeat orders re-check suitability, and there is no auto-shipping or subscription. You can compare options on all weight loss treatments, or read our guide to buying tirzepatide in the UK with all doses available.

Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice.